Articles: 29.10 October 2018

The barriers around antibiotic development

In this editorial, Rupert Payne, Consultant Editor for Prescriber, discusses the current barriers around antibiotic development alongside the important advances in chemistry, molecular biology, genetics and bioinformatics that may all contribute to the development of new antimicrobials.

More details...

How artificial intelligence is transforming healthcare

Artificial intelligence (AI) is already beginning to transform many aspects of healthcare, from offering advice to interpreting scans. This article discusses the progress that has been made so far and the AI-based applications we are likely to see in the near future

More details...

Current recommended management of tuberculosis

Despite reductions in overall case numbers both globally and in the UK, tuberculosis (TB) remains a major health problem. Here, the authors discuss the pathogenesis of TB and important aspects of management, alongside recent developments in epidemiology, diagnostics and treatment

More details...

Diagnosis and management of ADHD in children and adults

In March, NICE updated its guidance on the diagnosis and management of attention deficit hyperactivity disorder (ADHD) for the first time in 10 years. This article provides a summary of the new guideline’s main recommendations

More details...

Improving the diagnosis of autism spectrum disorder

Delays in the diagnosis of autism spectrum disorder (ASD) in children and young people are all too common and cause real anguish for those affected and their families. This article assesses the scale of the problem and discusses possible reasons and solutions

More details...

Simplifying prescribing data: OpenPrescribing two years on

OpenPrescribing is an online service launched in 2016 that facilitates the analysis of NHS primary care prescribing data in order to improve the quality and cost-effectiveness of prescribing. In this article, Joy Ogden talks to its founders Dr Ben Goldacre and Dr Peter Brindle about what the service has achieved since its launch, and their plans for its future development

More details...

Benralizumab for the treatment of severe eosinophilic asthma

Benralizumab (Fasenra) is a new anti-interleukin-5 monoclonal antibody therapy for the management of severe uncontrolled eosinophilic asthma. This article discusses its properties, clinical trial efficacy and adverse effects

More details...

Latest guidance updates

Steve Chaplin provides a brief summary of the latest guidance updates from

More details...

Web design and marketing agency Leamington Spa